Remove Eczema Remove Pharmaceutical Remove Safety
article thumbnail

Oh, The Places Dermatology Will Go in 2024!

The Dermatology Digest

“It has great efficacy and safety and is oral… [This means] no shot and no risk of anaphylaxis.” Dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc., Upadacitinib’s (Rinvoq, AbbVie) 5-yr safety data show that it is REALLY SAFE and effective in AD, and abrocitinib (Cibinqo, Pfizer) is safe as well.” What’s next? “We

article thumbnail

LEVEL UP Period 2 Data: AD Patients Who Switched From Dupilumab to Upadacitinib Hit Higher Treatment Targets

The Dermatology Digest

Learn more about LEVEL UP, the first head-to-head trial in AD assessing upadacitinib (Rinvoq, AbbVie) at a starting dose of 15mg daily vs. dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals) at its labeled dose, in Raising the Bar in Atopic Dermatitis (AD): Unpacking the practice-changing implications of the LEVEL-Up study in AD.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Label Update: FDA Green Lights Dupilumab for AD Patients With Moderate-to-Severe Hand and Foot Involvement

The Dermatology Digest

Food and Drug Administration (FDA) has updated the label for dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc. and Sanofi), adding efficacy and safety data for people aged 12 years and older with atopic dermatitis (AD) and uncontrolled moderate-to-severe hand and/or foot involvement. and Sanofi report. “We

article thumbnail

AD Pipeline Watch: Aslan Reports “Spectacular Results” in Phase 2 Study of Eblasakimab That Included Some Dupilumab-experienced Patients

The Dermatology Digest

Adult atopic dermatitis (AD) patients previously treated with dupilumab (Dupixent, Regeneron and Sanofi) who received 400mg eblasakimab weekly achieved Eczema Area Severity Index (EASI) 90, and 66.7% Treatment was well-tolerated and no new safety signals were identified.

article thumbnail

Retinol Serum: Is It Safe for Kids and Teens?

First Derm

Social media significantly influences the popularity of retinol among young people, leading to increased experimentation without considering safety. However, there are concerns about the safety of using retinol on younger skin due to the physiological differences between children’s and adults’ skin.

Retinol 104
article thumbnail

10 Key Causes of Dry, Itchy Scalp and How to Manage Them Effectively

First Derm

Skin Conditions (Eczema, Psoriasis, Contact Dermatitis) as Causes of Dry, Itchy Scalp Various skin conditions can lead to a dry, itchy scalp: a. Eczema (Dermatitis): Symptoms : Red, itchy, scaly patches on the scalp. 7] Triggers and Aggravators Common for Eczema and Psoriasis : Stress, hormonal changes, and environmental factors.

article thumbnail

The Role of Phototherapy in Inflammatory Skin Disease

The Dermatology Digest

According to Dr. Richard, today she uses many approaches, including biologics (as monotherapy and in combination), as well as phototherapy, to treat patients with psoriasis, eczema, vitiligo, and a “laundry list” of other skin diseases that respond to light. It has a great [safety and efficacy] profile. It’s a great adjunct therapy.

Eczema 36